Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on February 12, 2009

Arteriosclerosis, Thrombosis, and Vascular Biology. 2009
Published online before print February 12, 2009, doi: 10.1161/ATVBAHA.108.183384
A more recent version of this article appeared on May 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
29/5/761    most recent
ATVBAHA.108.183384v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Villa-Bellosta, R.
Right arrow Articles by Sorribas, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Villa-Bellosta, R.
Right arrow Articles by Sorribas, V.

Submitted on October 1, 2008
Accepted on February 4, 2009

Phosphonoformic Acid Prevents Vascular Smooth Muscle Cell Calcification by Inhibiting Calcium-Phosphate Deposition

Ricardo Villa-Bellosta and Víctor Sorribas *

From the Laboratory of Molecular Toxicology, University of Zaragoza, Spain.

* To whom correspondence should be addressed. E-mail: sorribas{at}unizar.es.

Objective—The role of inorganic phosphate in the pathogenesis of vascular calcification (VC) has been studied extensively in recent years. Phosphonoformic acid (PFA), an inhibitor of type II Pi transporters, has been traditionally used to study the involvement of Pi transport in VC, because PFA also prevents calcium deposition in vitro. However, aortic vascular smooth muscle cells (VSMCs) only express PFA-resistant, type III transporters (Pit-1 and Pit-2). Therefore, in this article we have studied the mechanism of VC prevention by PFA.

Methods and Results—Radiotracer Pi uptake in rat VSMCs was not inhibited at the concentrations at which PFA prevents calcification. Alternative mechanisms whereby PFA could prevent calcification, such as cytotoxicity or phosphodiesterase inhibition, have also been excluded. The progression of calcification also took place in fixed cells. The kinetics of VC prevention by PFA, pyrophosphate, phosphonoacetate, and bisphosphonates was similar in live and fixed cells, showing mean effective concentrations in the micromolar range.

Conclusions—PFA mainly prevents VC through a physicochemical mechanism that is independent of any cellular metabolic activity, including Pi transport. Conversely, PFA seems to act similarly to its chemical analogues, inorganic pyrophosphate, and bisphosphonates, as suggested decades ago.


Key words: phosphonoformic acid • foscarnet • vascular calcification • phosphate transport • Pit-1




This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
R. Villa-Bellosta and V. Sorribas
Different effects of arsenate and phosphonoformate on Pi transport adaptation in opossum kidney cells
Am J Physiol Cell Physiol, January 1, 2009; 297(3): C516 - C525.
[Abstract] [Full Text] [PDF]